# Rituximab in Rheumatoid Arthritis Lung Disease

> **NCT00578565** · PHASE3 · COMPLETED · sponsor: **Eric Matteson** · enrollment: 10 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Interstitial Pneumonia

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00578565
- **Lead sponsor:** Eric Matteson
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578565, "Rituximab in Rheumatoid Arthritis Lung Disease". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00578565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*